Athira Pharma has been granted a patent for a method of treating Parkinson’s Disease and Lewy body diseases by administering ATH-1017. The method involves administering specific doses of the compound to patients in need. GlobalData’s report on Athira Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Athira Pharma, Human telomerase RT biomarker was a key innovation area identified from patents. Athira Pharma's grant share as of May 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11998556B2) discloses a method for treating Parkinson's disease (PD) and/or Lewy body disease or disorder(s) (LBD) by administering 40 or 70 mg per day of a compound of formula A19 to patients between the ages of 40 and 85. The treatment aims to improve motor disorder symptoms, slow the decline in daily living activities and verbal fluency, stabilize or improve cognitive scores, and reduce the rate of decline in various assessment scales related to Alzheimer's disease and Parkinson's disease.
Furthermore, the method outlined in the patent involves administering the compound of formula A19 or its pharmaceutically acceptable salt via subcutaneous injection to patients at different stages of PD or LBD. The treatment is designed to show noticeable effects within specific time frames, ranging from at least 2 weeks to 26 weeks after the start of therapy. Additionally, the patent covers variations in dosage, including the administration of 40 mg per day of the compound of formula A19 or its salt, emphasizing the potential benefits for patients diagnosed with Parkinson's disease dementia (PDD) or probable idiopathic Parkinson's disease, or probable LBD.
To know more about GlobalData’s detailed insights on Athira Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
